Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.43 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 2/20 | 0.38 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.37 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.37 |
| ▸ | TPSD1 | Q9BZJ3 | 2/20 | 0.37 |
| ▸ | TPSG1 | Q9NRR2 | 2/20 | 0.37 |
| ▸ | CKS1B | P61024 | 1/20 | 0.36 |
| ▸ | SKP1 | P63208 | 1/20 | 0.36 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.36 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.36 |
| ▸ | DRD2 | P14416 | 2/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
| ▸ | ACE | P12821 | 1/20 | 0.35 |
| ▸ | CTSS | P25774 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4717209 | 1.00 | MALT1 (0.43) | MALT1KCNA5MEN1GAAKMT2A | |
| SCHEMBL1637220 | 0.94 | KMT2A (0.47) | MALT1KCNA5MEN1GAAKMT2A | |
| SCHEMBL4599868 | 0.94 | KMT2A (0.47) | MALT1KCNA5MEN1GAAKMT2A | |
| SCHEMBL4600039 | 0.94 | KMT2A (0.47) | MALT1KCNA5MEN1GAAKMT2A | |
| SCHEMBL2292771 | 0.93 | TPSAB1 (0.44) | MALT1MEN1GAAKMT2ATPSAB1 | |
| SCHEMBL4600306 | 0.93 | TPSAB1 (0.44) | MALT1MEN1GAAKMT2ATPSAB1 | |
| SCHEMBL4599808 | 0.93 | TPSAB1 (0.44) | MALT1MEN1GAAKMT2ATPSAB1 | |
| SCHEMBL4600478 | 0.92 | TPSAB1 (0.43) | MALT1MEN1GAAKMT2ATPSAB1 | |
| SCHEMBL4719257 | 0.91 | MALT1 (0.41) | MALT1KCNA5MEN1GAAKMT2A | |
| SCHEMBL4599020 | 0.89 | SYK (0.40) | MALT1KCNA5MEN1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4371982-A2 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX Pharmaceuticals, Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| EP-3583096-B1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS INC (US) | 2024-03-27 | — | — | EP | disclosed |
| US-20230133667-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS INC (US) | 2023-05-04 | — | — | US | disclosed |
| WO-2022234867-A1 | SULFONAMIDE HAVING MMP 7-INHIBITING ACTION | 大正製薬株式会社 | 2022-11-10 | — | — | WO | disclosed |
| US-20210198316-A9 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) | 2021-07-01 | — | — | US | disclosed |
| CN-110520413-A | Big ring broad-spectrum antibiotic | RQX PHARMACEUTICALS INC | 2019-11-29 | — | — | CN | disclosed |
| US-20080171783-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE | MIGENIX INC. (CA) | 2008-07-17 | — | — | US | disclosed |
| EP-1910279-A2 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | MIGENIX INC. (CA) | 2008-04-16 | — | — | EP | disclosed |
| US-20070021434-A1 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | MIGENIX INC. (CA) | 2007-01-25 | — | — | US | disclosed |
| WO-2007002639-A2 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | MIGENIX INC. (CA) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021434-A1 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | HAVCR2, ADAR, NSUN2 | MALT1 4428/4885KCNA5 4808/4885MEN1 4687/4885 |
| US-20080171783-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE | POLQ, POLI, POLH | MALT1 1060/4885KCNA5 4845/4885MEN1 3230/4885 |
| US-20210198316-A9 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | MRPL21, PEPD, CTSC | MALT1 3363/4885KCNA5 3409/4885MEN1 2531/4885 |
| US-20230133667-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | MRPL21, PEPD, CTSC | MALT1 3363/4885KCNA5 3409/4885MEN1 2531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.